Clinical characteristics of patients
| No. . | aGVHD prophylaxis . | Oral CGVHD severity . | NIH Global CGVHD Severity Score* . | Number of organ systems affected . | cGVHD onset . | Months after HSCT . | Systemic Immunosuppression at the time of evaluation . |
|---|---|---|---|---|---|---|---|
| 1 | CSA-MTX | Severe | Severe | 4 | Progressive | 13 | Prednisone, TL, MMF, ECP |
| 2 | CSA-MTX | Severe | Moderate | 4 | De novo | 9 | Prednisone, CSA |
| 3 | CSA-Sirolimus | Severe | Moderate | 3 | De novo | 6 | Prednisone |
| 4 | TL-MTX | Severe | Moderate | 4 | Progressive | 9 | Prednisone, TL, MMF |
| 5 | TL-MTX | Severe | Severe | 5 | Progressive | 46 | Prednisone, HCQ, TL, MMF, ECP |
| 6 | CSA-MMF | Severe | Severe | 4 | Progressive | 55 | Prednisone, MMF, SL, rituximab |
| 7 | CSA | Severe | Moderate | 4 | Progressive | 28 | Prednisone, TL, MMF |
| 8 | CSA | Severe | Severe | 6 | Quiescent | 64 | Hydrocortisone, CSA, MMF |
| 9 | CSA-Sirolimus | Severe | na | na | De novo | 6 | None |
| 10 | CSA-Sirolimus | Severe | Moderate | 6 | De novo | 6 | CSA |
| 11 | CSA-MTX | Severe | Moderate | 2 | Progressive | 5 | None |
| 12 | CSA-MTX | Severe | na | na | Quiescent | 7 | None |
| 13 | CSA-MTX | Mild | Severe | 5 | Quiescent | 147 | None |
| 14 | CSA-MTX | Mild | Moderate | 3 | Progressive | 33 | CSA, MMF |
| 15 | CSA | Mild | Severe | 5 | Progressive | 58 | Prednisone, TL, HCQ |
| 16 | CSA-MTX | Mild | Severe | 7 | Quiescent | 205 | MMF, CSA, ECP |
| 17 | CSA-MTX | Mild | Moderate | 3 | Quiescent | 100 | Prednisone |
| 18 | CSA-MTX | Mild | Severe | 4 | De novo | 22 | Prednisone, TL |
| 19 | ATG-unknown | Mild | Moderate | 5 | De novo | 41 | MMF |
| 20 | CSA-MTX | Mild | na | na | Quiescent | 29 | None |
| 21 | CSA-MTX | Mild | Severe | 3 | Progressive | 159 | Prednisone, CSA |
| 22 | CSA-MTX | Mild | Moderate | 6 | Progressive | 5 | Prednisone, CSA |
| 23 | CSA | Mild | Severe | 6 | Progressive | 55 | TL, MMF, ECP |
| 24 | TL-MMF | Mild | Moderate | 6 | Progressive | 12 | CSA |
| 25 | TL | Mild | Severe | 3 | Quiescent | 29 | None |
| 26 | CSA-MTX | Mild | na | na | De novo | 27 | Prednisone |
| 27 | Unknown | Mild | Moderate | 6 | Quiescent | 43 | Methylprednisolone, TL, MMF |
| 28 | CSA | Mild | na | na | De novo | 35 | Prednisone |
| 29 | CSA-MTX | None | Moderate | 3 | De-novo | 27 | None |
| 30 | CSA | None | Mild | 2 | Progressive | 39 | None |
| 31 | Unknown | None | Severe | 6 | Progressive | 59 | TL, MMF |
| 32 | CSA-Sirolimus | None | Mild | 2 | De novo | 12 | Prednisone, MMF, CSA |
| 33 | TL-MTX | None | Moderate | 3 | De novo | 28 | None |
| 34 | CSA-MMF | None | Severe | 6 | Quiescent | 22 | Hydrocortisone, CSA |
| 35 | CSA-MTX | None | No cGVHD | 0 | No cGVHD | 3 | CSA |
| 36 | CSA-MTX | None | No cGVHD | 0 | No cGVHD | 73 | None |
| 37 | CSA-MTX | None | No cGVHD | 0 | No cGVHD | 6 | CSA |
| No. . | aGVHD prophylaxis . | Oral CGVHD severity . | NIH Global CGVHD Severity Score* . | Number of organ systems affected . | cGVHD onset . | Months after HSCT . | Systemic Immunosuppression at the time of evaluation . |
|---|---|---|---|---|---|---|---|
| 1 | CSA-MTX | Severe | Severe | 4 | Progressive | 13 | Prednisone, TL, MMF, ECP |
| 2 | CSA-MTX | Severe | Moderate | 4 | De novo | 9 | Prednisone, CSA |
| 3 | CSA-Sirolimus | Severe | Moderate | 3 | De novo | 6 | Prednisone |
| 4 | TL-MTX | Severe | Moderate | 4 | Progressive | 9 | Prednisone, TL, MMF |
| 5 | TL-MTX | Severe | Severe | 5 | Progressive | 46 | Prednisone, HCQ, TL, MMF, ECP |
| 6 | CSA-MMF | Severe | Severe | 4 | Progressive | 55 | Prednisone, MMF, SL, rituximab |
| 7 | CSA | Severe | Moderate | 4 | Progressive | 28 | Prednisone, TL, MMF |
| 8 | CSA | Severe | Severe | 6 | Quiescent | 64 | Hydrocortisone, CSA, MMF |
| 9 | CSA-Sirolimus | Severe | na | na | De novo | 6 | None |
| 10 | CSA-Sirolimus | Severe | Moderate | 6 | De novo | 6 | CSA |
| 11 | CSA-MTX | Severe | Moderate | 2 | Progressive | 5 | None |
| 12 | CSA-MTX | Severe | na | na | Quiescent | 7 | None |
| 13 | CSA-MTX | Mild | Severe | 5 | Quiescent | 147 | None |
| 14 | CSA-MTX | Mild | Moderate | 3 | Progressive | 33 | CSA, MMF |
| 15 | CSA | Mild | Severe | 5 | Progressive | 58 | Prednisone, TL, HCQ |
| 16 | CSA-MTX | Mild | Severe | 7 | Quiescent | 205 | MMF, CSA, ECP |
| 17 | CSA-MTX | Mild | Moderate | 3 | Quiescent | 100 | Prednisone |
| 18 | CSA-MTX | Mild | Severe | 4 | De novo | 22 | Prednisone, TL |
| 19 | ATG-unknown | Mild | Moderate | 5 | De novo | 41 | MMF |
| 20 | CSA-MTX | Mild | na | na | Quiescent | 29 | None |
| 21 | CSA-MTX | Mild | Severe | 3 | Progressive | 159 | Prednisone, CSA |
| 22 | CSA-MTX | Mild | Moderate | 6 | Progressive | 5 | Prednisone, CSA |
| 23 | CSA | Mild | Severe | 6 | Progressive | 55 | TL, MMF, ECP |
| 24 | TL-MMF | Mild | Moderate | 6 | Progressive | 12 | CSA |
| 25 | TL | Mild | Severe | 3 | Quiescent | 29 | None |
| 26 | CSA-MTX | Mild | na | na | De novo | 27 | Prednisone |
| 27 | Unknown | Mild | Moderate | 6 | Quiescent | 43 | Methylprednisolone, TL, MMF |
| 28 | CSA | Mild | na | na | De novo | 35 | Prednisone |
| 29 | CSA-MTX | None | Moderate | 3 | De-novo | 27 | None |
| 30 | CSA | None | Mild | 2 | Progressive | 39 | None |
| 31 | Unknown | None | Severe | 6 | Progressive | 59 | TL, MMF |
| 32 | CSA-Sirolimus | None | Mild | 2 | De novo | 12 | Prednisone, MMF, CSA |
| 33 | TL-MTX | None | Moderate | 3 | De novo | 28 | None |
| 34 | CSA-MMF | None | Severe | 6 | Quiescent | 22 | Hydrocortisone, CSA |
| 35 | CSA-MTX | None | No cGVHD | 0 | No cGVHD | 3 | CSA |
| 36 | CSA-MTX | None | No cGVHD | 0 | No cGVHD | 73 | None |
| 37 | CSA-MTX | None | No cGVHD | 0 | No cGVHD | 6 | CSA |
aGVHD indicates acute graft-versus-host disease; ATG, anti-thymocyte globulin; CSA, cyclosporine; ECP, extracorporeal photopheresis; HCQ, hydroxychloroquine; HSCT, hematopoietic stem cell transplant; MMF, mycophenolate mofetil; MTX, methotrexate; na, not available; SL, Sirolimus; and TL, tacrolimus.
Scoring based upon the National Institutes of Health (NIH) Consensus Development Project on criteria for clinical trials in cGVHD.9